Thank you for submitting your abstract for the ESTRO 37 Congress.

**PLEASE NOTE THAT FURTHER CHANGES TO YOUR ABSTRACT ARE NO LONGER POSSIBLE.**

If you have further questions or remarks, please contact abstracts@estro.org

This is an overview of your abstract number E37-2840:

**Session title**

**Track** Late Breaking Abstract Submission

**Topic** Late Breaking Abstracts

**Presentation preference** Oral presentation

**Abstract title** Ultrahypofractionation for prostate cancer: Outcome from the Scandinavian phase 3 HYPO-RT-PC trial

A. WIDMARK\(^1\), A. GUNNLAUGSSON\(^2\), L. BECKMAN\(^3\), C. THELLENBERG-KARLSSON\(^1\), M. HOYER\(^4\), M. LAGERLUND\(^4\), P. FRANSSON\(^5\), B. TAVELIN\(^1\), D.B. NORMAN\(^6\), J. KINDBLOM\(^7\), C. GINMAN\(^8\), B. JOHANSSON\(^9\), M. SEKE\(^10\), K. BJÖRLINGER\(^11\), M. ÅGRUP\(^12\), E. KJELLEN\(^13\), L. FRANZEN\(^1\), P. NILSSON\(^14\).

\(^1\)UMEA UNIVERSITY, RADIATION SCIENCES/ONKOLOGY, UMEÅ, SWEDEN.

\(^2\)SKÅNE UNIVERSITY HOSPITAL- LUND UNIVERSITY, DEPT. OF ONCOLOGY AND RADIATION PHYSICS, LUND, SWEDEN.

\(^3\)UMEÅ UNIVERSITY, SUNDSVALL HOSPITAL- SUNDSVALL- AND DEPT. RADIATION SCIENCES, SUNDSVALL, SWEDEN.

\(^4\)AARHUS UNIVERSITY HOSPITAL, DANISH CENTRE FOR PARTICLE THERAPY, AARHUS, DENMARK.

\(^5\)KALMAR HOSPITAL, DEPARTMENT OF ONCOLOGY, KALMAR, SWEDEN.

\(^6\)UMEA UNIVERSITY HOSPITAL, REGIONAL CANCER CENTRE NORTH, UMEÅ, SWEDEN.

\(^7\)UNIVERSITY OF GOTHENBURG, DEPARTMENT OF ONCOLOGY- INSTITUTE OF CLINICAL SCIENCES- THE SAHLGRENSKA ACADEMY, GOTHENBURG, SWEDEN.

\(^8\)KARLSTAD CENTRAL HOSPITAL, DEPARTMENT OF ONCOLOGY, KARLSTAD, SWEDEN.

\(^9\)ÖREBRO UNIVERSITY HOSPITAL AND ÖREBRO UNIVERSITY, DEPARTMENT OF ONCOLOGY, ÖREBRO, SWEDEN.

\(^10\)CENTRALLASARETTET VÄXJÖ, DEPARTMENT OF ONCOLOGY-, VÄXJÖ, SWEDEN.

\(^11\)JÖNKÖPING HOSPITAL, DEPARTMENT OF ONCOLOGY, VÄXJÖ, SWEDEN.

\(^12\)LINKÖPING UNIVERSITY HOSPITAL-, DEPARTMENT OF ONCOLOGY-, LINKÖPING, SWEDEN.

\(^13\)SKÅNE UNIVERSITY HOSPITAL- LUND UNIVERSITY-, DEPT. OF ONCOLOGY AND RADIATION PHYSICS-, LUND, SWEDEN.

\(^14\)SKÅNE UNIVERSITY HOSPITAL- LUND UNIVERSITY-, DEPT. OF ONCOLOGY AND RADIATION PHYSICS, LUND, SWEDEN.

**Purpose or Objective**

Hypofractionated (HF) radiotherapy (RT) for prostate cancer has gained increased attention due to its proposed high radiation-fraction sensitivity. Recent reports from randomised studies comparing moderately hypofractionated (M-HF) and conventionally fractionated (CF) radiotherapy (RT) have supported the value of M-HF. Until now there are no prospective randomised data for ultrahypofractionation (U-HF) regimens. Recently, we presented 2-year toxicity results from the first large randomised trial on U-HF versus CF; the Scandinavian HYPO-RT-PC study\(^1\). We now report the first results on primary outcome and updated toxicity data from this trial.

**Material and Methods**

The Scandinavian HYPO-RT-PC study is a randomised, phase III, non-inferiority trial that recruited patients with intermediate/high-risk prostate cancer (T1c-T3a, PSA ≤20 with one or two of the following risk factors; T3a or Gleason ≥7 or PSA >10). Patients were randomly assigned (1:1) to either CF (n=602), 39 x 2.0 Gy=78.0 Gy over 8 weeks or U-HF...
(n=598), 7 x 6.1 Gy=42.7 Gy over 2.5 weeks (RT every other weekday). No androgen deprivation therapy was allowed. The treatment schedules were designed to be equieffective for late normal tissue complication probability (α/β=3 Gy). Image guided RT (3D CRT or VMAT) based on fiducial markers was delivered to the prostate only (CTV) with a 7 mm isotropic CTV-PTV margin. The primary endpoint was time to biochemical or clinical failure and the treatment groups were compared by means of a Cox proportional hazards model. To conclude non-inferiority, a critical hazard ratio (HR) of 1.338 (one-sided α=0.025) was pre-specified, corresponding to a margin of 4% at 5 years. Physician’s evaluation of side-effects was performed according to a modified RTOG scale. The trial number is ISRCTN45905321.

Results

Between July 2005 to November 2015, 1200 patients from 12 centres were randomised. Analysis was made per protocol and 1180 patients (591 CF and 589 U-HF) with a median follow-up time of 59.7 months [95%CI 57.6−51.8] were eligible for evaluation of primary outcome. The total number of events during the follow-up period was 102 and 100 in the CF and the U-HF group, respectively. The proportion of patients, free of biochemical or clinical failure at 5 years, was 83.8% [95%CI 80.4−87.3] in the CF arm and 83.7% [95%CI 80.3−87.1] in the U-HF arm (Fig. 1). U-HF was found to be non-inferior to CF: HR (95% CI) = 0.992 (0.753, 1.307).

There were no significant differences in the prevalence of physician reported late grade 2+ toxicity at four/six years (CF vs. U-HF): urinary 4.1% vs. 4.1%, p=0.38 / 3.5% vs. 2.5%, p=0.75 and bowel: 1.6% vs. 1.6%, p=1.00 / 2.3% vs. 1.2%, p=0.69.

Fig. 1. Kaplan-Meier estimated failure-free survival (1=CF, 2=U-HF)

Conclusion

Ultrahypofractionated RT (42.7 Gy/7 fractions) is non-inferior to conventionally fractionated RT (78 Gy/39 fractions). U-HF resulted in a low incidence of side-effects with no significant differences compared to CF for late GU and GI toxicity.

I have no potential conflict of interest to disclose

Keyword Prostate Cancer

Kind regards,
ESTRO Office

This is an automated message – please do not reply directly to this e-mail